SNCA and Parkinson disease: In another example, the observed reduction in α-synuclein levels following the demethylation of H3K4 at the SNCA promoter using CRISPR/Cas9 [120] suggests that a possible future PD treatment avenue might involve region-specific methylation or demethylation of DNA or certain histones to reverse epigenetic changes in the disease.